Giroux, Nicholas S.
Ding, Shengli
McClain, Micah T.
Burke, Thomas W.
Petzold, Elizabeth
Chung, Hong A.
Rivera, Grecia O.
Wang, Ergang
Xi, Rui
Bose, Shree
Rotstein, Tomer
Nicholson, Bradly P.
Chen, Tianyi
Henao, Ricardo
Sempowski, Gregory D.
Denny, Thomas N.
De Ussel, Maria Iglesias
Satterwhite, Lisa L.
Ko, Emily R.
Ginsburg, Geoffrey S.
Kraft, Bryan D.
Tsalik, Ephraim L.
Shen, Xiling
Woods, Christopher W.
Funding for this research was provided by:
Defense Advanced Research Projects Agency (HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069, HR0011-17-2-0069)
National Heart, Lung, and Blood Institute (K08HL130557)
Article History
Received: 23 March 2022
Accepted: 28 June 2022
First Online: 9 July 2022
Change Date: 20 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-33323-8
Competing interests
: MTM reports grants on biomarker diagnostics from the Defense Advanced Research Projects Agency (DARPA), National Institutes of Health (NIH), Sanofi, and the Department of Veterans Affairs. TWB reports grants from DARPA and is a consultant for and holds equity in Predigen and Biomeme. MTM, TWB, ELT, GSG, and CWW report patents pending on Molecular Methods to Diagnose and Treat Respiratory Infections. ELT reports grants on biomarker diagnostics from DARPA, the NIH/Antibacterial Resistance Leadership Group (ARLG); an ownership stake in Predigen and Biomeme; consultancy fees from bioMerieux; GSG reports an ownership stake in Predigen and Biomeme; CWW reports grants on biomarker diagnostics from DARPA, NIH/ARLG, Predigen, and Sanofi; and has received consultancy fees from bioMerieux, Roche, Biofire, Giner, and Biomeme. All other authors NSG, SD, EP, HAC, GOR, EW, RX, SB, TR, BPN, TC, RH, GDS, TND, MIDU, LLS, ERK, BDK and XS have no competing interests to report.